Published in Oncogene on February 24, 2005
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Loss of Dact1 disrupts planar cell polarity signaling by altering dishevelled activity and leads to posterior malformation in mice. J Biol Chem (2010) 1.17
Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network. Diabetes (2008) 1.13
DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res (2013) 1.10
Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol (2013) 1.09
All Dact (Dapper/Frodo) scaffold proteins dimerize and exhibit conserved interactions with Vangl, Dvl, and serine/threonine kinases. BMC Biochem (2011) 1.07
DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol (2014) 0.99
Repair and regeneration: opportunities for carcinogenesis from tissue stem cells. J Cell Mol Med (2006) 0.98
Dpr Acts as a molecular switch, inhibiting Wnt signaling when unphosphorylated, but promoting Wnt signaling when phosphorylated by casein kinase Idelta/epsilon. PLoS One (2009) 0.97
Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol (2011) 0.94
Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A (2008) 0.90
Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma. Epigenetics (2013) 0.89
Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia. BMC Cancer (2012) 0.89
Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer. Am J Cancer Res (2014) 0.87
Protein kinase A-mediated 14-3-3 association impedes human Dapper1 to promote dishevelled degradation. J Biol Chem (2011) 0.87
Oncogenic function of DACT1 in colon cancer through the regulation of β-catenin. PLoS One (2012) 0.86
Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance. Int J Clin Exp Med (2015) 0.84
Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-κB signaling pathway. Mol Med (2012) 0.84
Liver stem cells and molecular signaling pathways in hepatocellular carcinoma. Gastrointest Cancer Res (2007) 0.83
Cytoplasmic HDPR1 is involved in regional lymph node metastasis and tumor development via beta-catenin accumulation in esophageal squamous cell carcinoma. J Histochem Cytochem (2011) 0.80
DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. Am J Cancer Res (2014) 0.79
Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol (2007) 0.79
Disruption of the Dapper3 gene aggravates ureteral obstruction-mediated renal fibrosis by amplifying Wnt/β-catenin signaling. J Biol Chem (2013) 0.78
Reduced expression of DACT2 promotes hepatocellular carcinoma progression: involvement of methylation-mediated gene silencing. World J Surg Oncol (2013) 0.77
Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol (2016) 0.76
DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells. Oncotarget (2016) 0.75
Association analysis of DACT1 genetic variants and gastric cancer risk in a Chinese Han population: a case-control study. Onco Targets Ther (2016) 0.75
Retinoic acid negatively regulates dact3b expression in the hindbrain of zebrafish embryos. Gene Expr Patterns (2014) 0.75
MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma. Oncotarget (2017) 0.75
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology (2002) 2.90
Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet (2010) 2.74
Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology (2003) 2.73
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg (2002) 2.42
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A (2011) 2.17
High frequency of chimerism in transplanted livers. Hepatology (2003) 2.15
Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.98
Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol (2010) 1.97
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology (2010) 1.88
Immediate and long-term outcomes of hepatectomy for hepatolithiasis. Surgery (2004) 1.86
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology (2010) 1.85
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg (2004) 1.79
Radiofrequency ablation for subcapsular hepatocellular carcinoma. Ann Surg Oncol (2004) 1.77
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res (2006) 1.76
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol (2002) 1.75
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res (2005) 1.73
Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl (2004) 1.72
TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci (2013) 1.66
Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics (2006) 1.65
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation (2003) 1.61
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis (2005) 1.59
Choledochal cysts in adults. Arch Surg (2002) 1.59
Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.58
Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem (2003) 1.55
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology (2012) 1.55
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res (2012) 1.52
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology (2010) 1.52
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
New diagnostic criteria and severity assessment of acute cholecystitis in revised Tokyo Guidelines. J Hepatobiliary Pancreat Sci (2012) 1.49
Surgical treatment of patients with acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.49
Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg (2008) 1.44
Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl (2003) 1.44
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg (2005) 1.44
Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.43
Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am (2003) 1.42
Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res (2003) 1.41
Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res (2003) 1.40
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A (2005) 1.40
TG13 surgical management of acute cholecystitis. J Hepatobiliary Pancreat Sci (2013) 1.39
Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics (2007) 1.39
An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene (2005) 1.38
Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology (2009) 1.34
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology (2006) 1.33
Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg (2007) 1.30
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol (2008) 1.28
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis (2008) 1.28
Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res (2003) 1.28
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol (2005) 1.26
Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer (2003) 1.24
New diagnostic criteria and severity assessment of acute cholangitis in revised Tokyo Guidelines. J Hepatobiliary Pancreat Sci (2012) 1.23
Safety of duct-to-duct biliary reconstruction in right-lobe live-donor liver transplantation without biliary drainage. Transplantation (2004) 1.23
Portal hyperperfusion injury as the cause of primary nonfunction in a small-for-size liver graft-successful treatment with splenic artery ligation. Liver Transpl (2003) 1.21
The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res (2005) 1.21
Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg (2002) 1.21
The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl (2004) 1.20
Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.19
Methods and timing of biliary drainage for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.19
Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol (2004) 1.18
Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology (2007) 1.18
Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology (2007) 1.18
Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg (2003) 1.17
P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res (2007) 1.17
Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol (2002) 1.16
Living-donor liver transplantation: 12 years of experience in Asia. Transplantation (2003) 1.16
High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep (2004) 1.13
Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology (2012) 1.13
Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther (2006) 1.13
Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol (2002) 1.11
Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.11
Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol (2003) 1.11
Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int (2015) 1.11